Jemperli data show 76% complete response rate

Jemperli achieved a 76% complete response rate in MSI-H/dMMR rectal cancer patients.

What the company is saying

GSK plc is highlighting interim phase II AZUR-1 trial results showing that 76% of evaluable patients with MSI-H/dMMR locally advanced rectal cancer achieved a complete response to Jemperli (dostarlimab) monotherapy. The company frames this as a potential paradigm shift, emphasizing that 68% of patients sustained a clinical complete response for at least 12 months without surgery, and no disease recurrences have been reported among responders after a median follow-up of over two years. The announcement stresses the possibility of avoiding chemotherapy, radiation, and surgery for some patients, positioning Jemperli as a transformative option. Hesham Abdullah, Senior Vice President and Global Head of Oncology R&D at GSK, and Dr Andrea Cercek, Principal Investigator of AZUR-1, are quoted to reinforce the clinical significance and confidence in organ preservation. The company also notes that these data supported the recent US approval of Jemperli for this indication and that regulatory reviews are ongoing internationally through Project Orbis. The tone is confident and data-driven, with a focus on both efficacy and safety outcomes.

What the data suggests

The AZUR-1 trial enrolled 154 patients with stage II/III MSI-H/dMMR locally advanced rectal cancer, with 76% (110/144; 95% CI: 69%, 83%) of evaluable patients achieving a complete response to Jemperli monotherapy. Of these, 68% (98/144; 95% CI: 60%, 76%) had a sustained clinical complete response for at least 12 months without surgery, and 12 additional patients achieved a pathological complete response after surgery. No disease recurrences have been observed among responders after a median follow-up of more than two years. At the time of analysis, 47% (54/116; 95% CI: 37%, 56%) had achieved cCR12 as assessed by independent central review, with 38 more patients yet to reach the 12-month mark. Serious adverse reactions occurred in 20% of patients, with the most common being fatigue (32%), rash (22%), diarrhoea (18%), and pruritus (17%). Jemperli was permanently discontinued due to adverse reactions in 3% of patients. The treatment regimen was nine cycles over six months, with a 500mg intravenous infusion every three weeks. The data is robust for efficacy and safety, but there is no financial or commercial data disclosed.

Analysis

The announcement's tone is positive but proportionate to the disclosed clinical results. The majority of claims are realised and supported by detailed numerical data, including response rates, adverse event frequencies, and follow-up duration. Only a small fraction of statements are forward-looking, such as ongoing regulatory reviews and an upcoming conference presentation. There is no evidence of exaggerated language or narrative inflation; the release avoids broad commercial projections or unsubstantiated claims of impact. No large capital outlay or long-dated, uncertain returns are discussed. The absence of financial metrics (revenue, profit, cash flow) means the signal cannot be strong_positive, but the clinical data is robust and transparent. The gap between narrative and evidence is minimal, with all key efficacy and safety claims substantiated by the data.

Risk flags

• ●The primary risk is that these are interim phase II results from a single-arm trial; without a randomized comparator, the durability and generalizability of the response rates may be questioned by regulators or payers.
• ●Long-term safety and efficacy beyond the current median follow-up of two years remain unproven, and late recurrences or adverse events could emerge with longer observation.
• ●Regulatory approval outside the US is not guaranteed, as ongoing reviews through Project Orbis may result in additional data requirements or delays, impacting commercial rollout.
• ●The absence of financial data means the revenue and profit impact of Jemperli in this indication is currently unknown, limiting visibility into the drug's commercial value.
• ●Adverse reactions led to permanent discontinuation in 3% of patients and serious adverse events in 20%, which may affect uptake or require additional risk management strategies.

Bottom line

GSK's AZUR-1 trial data for Jemperli in MSI-H/dMMR locally advanced rectal cancer show a high 76% complete response rate and no disease recurrences among responders after more than two years, supporting the drug's recent US approval. The results are clinically impressive, particularly the 68% sustained response rate without surgery, but the lack of a randomized comparator and the single-arm design limit definitive conclusions about superiority over standard care. Safety is consistent with prior experience, though 20% experienced serious adverse reactions and 3% discontinued treatment. The absence of financial disclosures means investors cannot yet assess the commercial impact. The most immediate value is clinical, with regulatory and commercial benefits dependent on forthcoming approvals and market uptake. The key takeaway is that Jemperli is emerging as a potentially practice-changing therapy for a subset of rectal cancer patients, but financial upside will hinge on regulatory outcomes and real-world adoption.

Announcement summary

(LSE:GSK) GSK plc announced positive interim results from the phase II AZUR-1 trial evaluating Jemperli (dostarlimab) monotherapy in adults with stage II and III microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) locally advanced rectal cancer. In an exploratory analysis, 76% of evaluable patients (110/144; 95% CI: 69%, 83%) achieved a complete response to dostarlimab alone. Of these, 68% (98/144; 95% CI: 60%, 76%) achieved a sustained clinical complete response for at least 12 months (cCR12) without surgery, and 12 additional patients had a pathological complete response confirmed through tissue analysis after surgery. No disease recurrences have been reported among responders after a median follow-up of more than two years. The AZUR-1 trial met its primary objective, demonstrating that a clinically significant proportion of patients achieved cCR12. At the time of analysis, 47% of evaluable patients (54/116; 95% CI: 37%, 56%) had achieved cCR12 as assessed by independent central review, with an additional 38 participants having achieved a clinical complete response but not yet reaching the 12-month assessment timepoint. Serious adverse reactions occurred in 20% of patients receiving Jemperli, and the most common adverse reactions were fatigue (32%), rash (22%), diarrhoea (18%), and pruritus (17%). Jemperli was permanently discontinued due to adverse reactions in 3% of patients. The trial enrolled 154 patients who received nine cycles of dostarlimab over six months, administered as a 500mg intravenous infusion every three weeks. Regulatory reviews are ongoing in participating countries through Project Orbis, an FDA Oncology Center of Excellence initiative. Jemperli was discovered by AnaptysBio, Inc. and licensed to TESARO, Inc., with GSK responsible for ongoing research, development, commercialisation, and manufacturing. Around 5–10% of rectal cancers are MSI-H or dMMR. The findings supported the recent US approval of Jemperli in this indication. The results will be presented in a late-breaking oral session at the European Society for Medical Oncology (ESMO) Congress. Dr Andrea Cercek, MD, Section Head of Colorectal Cancer and Co-Director of the Center for Young Onset Colorectal and Gastrointestinal Cancer at Memorial Sloan Kettering Cancer Center, is the Principal Investigator of AZUR-1. GSK develops differentiated medicines for cancers across haematological, lung, gastrointestinal, genitourinary, and gynaecological cancers.

Disagree with this article?